(19)
(11) EP 4 337 666 A1

(12)

(43) Date of publication:
20.03.2024 Bulletin 2024/12

(21) Application number: 22806152.9

(22) Date of filing: 10.05.2022
(51) International Patent Classification (IPC): 
C07F 9/6558(2006.01)
C07D 401/12(2006.01)
C07D 417/12(2006.01)
C07D 471/04(2006.01)
C07F 9/572(2006.01)
C07D 209/16(2006.01)
C07D 405/12(2006.01)
C07D 417/14(2006.01)
C07D 491/048(2006.01)
C07F 9/6561(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 209/16; C07D 401/12; C07D 405/12; C07F 9/6561; C07D 417/14; C07D 471/04; C07D 417/12; C07F 9/5728; C07F 9/65586; C07D 491/107; C07D 489/08
(86) International application number:
PCT/CA2022/050733
(87) International publication number:
WO 2022/236407 (17.11.2022 Gazette 2022/46)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 10.05.2021 US 202163186497 P

(71) Applicant: London Pharmaceuticals and Research Corporation
London, ON N6G 0K4 (CA)

(72) Inventors:
  • CLARKE, Collin
    London, Ontario N6C 2N6 (CA)
  • MOUSTAFA, Mahmoud Mohamed Abdrabo
    London, Ontario N5X 3Y1 (CA)
  • MAYHOUB, Abdelrahman S.
    City Giza, 12354 (EG)

(74) Representative: Zeuner Summerer Stütz 
Patent- und Rechtsanwälte Partnerschaft Nußbaumstraße 8
80336 München
80336 München (DE)

   


(54) PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES